ArticleInvestigative ophthalmology & visual science2026
AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the therapeutic potential of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint pathway in experimental autoimmune uveitis (EAU) and to elucidate its role in regulating the retinal immune microenvironment. Methods: Seven days before EAU induction, Lewis rats received subretinal injections of adeno-associated virus serotype 8 (AAV8)/PD-L1. EAU was induced by immunization with interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant. Clinical inflammation scores were recorded on days 8, 10, 12, and 14 post-immunizations. Retinal function was evaluated by electroretinography (ERG) on day 12, and structural changes were assessed by optical coherence tomography (OCT). On day 14, eyes were harvested for histopathological examination, immunofluorescence, and flow cytometric analyses of leukocyte infiltration and cytokine expression. Normal rats injected with AAV8/PD-L1 were examined to assess retinal safety. Results: AAV8/PD-L1 markedly enhanced PD-L1 expression in the retina, resulting in significantly reduced intraocular inflammation and tissue damage compared with untreated EAU rats. The PD-L1 group showed lower anterior chamber inflammation scores (P < 0.05), decreased retinal T-cell and leukocyte infiltration (P < 0.05), and downregulated expression of IL-17. No structural or functional abnormalities were observed in normal eyes treated with AAV8/PD-L1. Conclusions: AAV8-mediated PD-L1 overexpression suppresses EAU progression by restoring retinal immune tolerance, attenuating inflammation, and preserving visual function. This approach offers a promising gene therapy strategy for local immune modulation in ocular autoimmune diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.